Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Cannabis topic
No spam. Unsubscribe anytime.
Senate agrees to expanded medical cannabis rules after heated debate
Summary
The Georgia Senate approved a House substitute to expand access to medical cannabis — renaming low-THC oil, allowing vaporized plant products, and adjusting patient and caregiver rules — after an extended, often contentious floor debate over public safety, clinical oversight and commercialization.
The Georgia Senate voted to agree to an amended House substitute of Senate Bill 220 on Thursday, approving a package that renames the current ‘‘low-THC oil’’ program as medical cannabis and broadens the forms and delivery methods that eligible patients may use.
SB 220, carried on the floor by the sponsor (Senator from the 6th), allows certain patients to access vaporized plant material and other cannabis products in addition to oils, sets possession limits by milligram rather than percent, extends a five-year registration option for patients with irreversible conditions, and requires physicians to apply a medical-judgment standard that benefits outweigh risks. The Senate adopted an amendment making issuance of an electronic registration card contingent on appropriation and put other guardrails in place. The motion to agree as amended passed 38–14.
Supporters, including veterans and members who said they have constituents with chronic pain or treatment-resistant conditions, argued the bill modernizes an outdated program and reduces barriers for patients who have not benefited from conventional pharmaceuticals. “Patients need to be free of pain,” one senator said, urging colleagues to focus on relief for cancer, chronic pain and other qualifying illnesses.
Opponents warned the bill moves the law beyond the narrowly targeted program originally approved for low-THC oil and into broader, high-THC products that can be inhaled and deliver rapid psychoactive effects. Critics said that raising allowable potency and expanding delivery methods risks stronger recreational use, enforcement complications for law enforcement, and potential mental-health effects. The chamber’s debate included exchanges about dosage limits, possession caps, the role of the Department of Public Health and the need for more clinical research.
The bill keeps physician judgment and requires a Georgia-practice nexus for prescribers. It also preserves a requirement that purchases occur in private settings and tightens marketing rules to prohibit child-targeted advertising and false medical claims. An anti-burden provision bars the department from imposing excessive fees or unduly burdensome rules on card issuance.
Senators on both sides urged additional research; panel proponents pointed to federal moves to remove barriers to study. The Senate’s passage sends the House-amended substitute forward in the legislative process under the terms the chamber adopted.
Next steps: The measure was agreed to as amended on the floor; supporters said implementing rules and appropriations for an electronic card system will determine how quickly patient access expands.
